|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
|
KR100704213B1
(ko)
*
|
2000-11-03 |
2007-04-10 |
테바 파마슈티컬 인더스트리즈 리미티드 |
아토르바스타틴 헤미-칼슘 ｖｉｉ형
|
|
IL156055A0
(en)
*
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
|
CA2622477A1
(en)
|
2000-12-27 |
2002-07-04 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of atorvastatin
|
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
|
BR0210666A
(pt)
*
|
2001-06-29 |
2004-10-05 |
Warner Lambert Co |
Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
|
|
US7074818B2
(en)
|
2001-07-30 |
2006-07-11 |
Dr. Reddy's Laboratories Limited |
Crystalline forms VI and VII of Atorvastatin calcium
|
|
AU2002255479B2
(en)
|
2001-07-30 |
2008-09-11 |
Dr. Reddy's Laboratories Ltd. |
Crystalline forms VI and VII of atorvastatin clacium
|
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
|
CA2475864A1
(en)
*
|
2002-02-15 |
2003-08-28 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
|
|
HRP20040767A2
(en)
|
2002-02-19 |
2004-12-31 |
Teva Pharma |
Desolvating solvates of atorvastatin hemi-calcium
|
|
ATE409476T1
(de)
*
|
2002-06-13 |
2008-10-15 |
Novartis Pharma Gmbh |
Calciumsalze von statinen aus indol
|
|
GB0218781D0
(en)
*
|
2002-08-13 |
2002-09-18 |
Astrazeneca Ab |
Chemical process
|
|
WO2004050618A2
(en)
*
|
2002-11-28 |
2004-06-17 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form f of atorvastatin hemi-calcium salt
|
|
EP1424324A1
(en)
*
|
2002-11-28 |
2004-06-02 |
Teva Pharmaceutical Industries Limited |
Crystalline form F of Atorvastatin hemi-calcium salt
|
|
GB0312896D0
(en)
|
2003-06-05 |
2003-07-09 |
Astrazeneca Ab |
Chemical process
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
CA2465693A1
(en)
*
|
2003-06-12 |
2004-12-12 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
UY28501A1
(es)
|
2003-09-10 |
2005-04-29 |
Astrazeneca Uk Ltd |
Compuestos químicos
|
|
GB0324791D0
(en)
|
2003-10-24 |
2003-11-26 |
Astrazeneca Ab |
Chemical process
|
|
CA2649054A1
(en)
|
2004-05-05 |
2005-11-10 |
Pfizer Products Inc. |
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|
|
JP2008506764A
(ja)
|
2004-07-20 |
2008-03-06 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
|
|
WO2006037125A1
(en)
|
2004-09-28 |
2006-04-06 |
Teva Pharmaceutical Industries Ltd. |
Process for preparing forms of atorvastatin calcium substantially free of impurities
|
|
CN101039906A
(zh)
|
2004-10-18 |
2007-09-19 |
特瓦制药工业有限公司 |
通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
|
|
WO2006046109A1
(en)
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
|
WO2006048894A1
(en)
*
|
2004-11-05 |
2006-05-11 |
Morepen Laboratories Limited |
Novel crystalline forms of atorvastatin calcium and processes for preparing them.
|
|
WO2006054308A2
(en)
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
|
CA2499047A1
(en)
|
2005-03-01 |
2006-09-01 |
Apotex Pharmachem Inc. |
Process for producing atorvastatin hemicalcium
|
|
AU2006281229A1
(en)
|
2005-08-15 |
2007-02-22 |
Arrow International Limited |
Crystalline and amorphous sodium atorvastatin
|
|
EP1924555B1
(en)
*
|
2005-08-15 |
2014-10-08 |
Arrow International Limited |
Process for the preparation of crystalline sodium atorvastatin
|
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
|
EP1808162A1
(en)
|
2005-11-21 |
2007-07-18 |
Teva Pharmaceutical Industries Ltd. |
Atorvastatin pharmaceutical formulation
|
|
EP1923057A1
(en)
|
2005-11-21 |
2008-05-21 |
Teva Pharmaceutical Industries Ltd |
Atorvastatin pharmaceutical formulation
|
|
ATE466840T1
(de)
|
2005-11-21 |
2010-05-15 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
|
|
US8080672B2
(en)
|
2005-12-13 |
2011-12-20 |
Teva Pharmaceutical Industries Ltd. |
Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
|
|
EP1810667A1
(en)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising amorphous atorvastatin
|
|
AU2007219107B2
(en)
*
|
2006-02-22 |
2012-12-06 |
Mylan Laboratories Ltd. |
New crystalline form of Atorvastatin hemi-calcium
|
|
JP2010520273A
(ja)
*
|
2007-03-02 |
2010-06-10 |
ドン・ア・ファーム・カンパニー・リミテッド |
ピロリルヘプタン酸誘導体の新規な結晶形態
|
|
US8664390B2
(en)
|
2007-06-29 |
2014-03-04 |
Generics (Uk) Limited |
Process for the introduction of hydroxyethoxy side chain in bosentan
|
|
WO2009007856A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Actavis Group Ptc Ehf |
Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
|
|
NZ585438A
(en)
|
2007-10-24 |
2012-09-28 |
Generics Uk Ltd |
Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
|
|
CA2712860C
(en)
|
2008-02-08 |
2014-11-18 |
Abhay Gaitonde |
Process for preparing bosentan
|
|
CA2741928A1
(en)
|
2008-11-03 |
2010-06-03 |
Generics [Uk] Limited |
Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
|
|
EP2373609B1
(en)
*
|
2008-12-19 |
2013-10-16 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2327682A1
(en)
*
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
CZ201039A3
(cs)
|
2010-01-19 |
2011-07-27 |
Zentiva, K. S |
Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
|
|
KR20120011249A
(ko)
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
|
CN102249978A
(zh)
*
|
2011-06-09 |
2011-11-23 |
浙江金立源药业有限公司 |
阿托伐他汀钙的ky晶型及制备方法
|
|
CN103483238B
(zh)
*
|
2013-08-20 |
2014-12-31 |
蚌埠丰原医药科技发展有限公司 |
阿托伐他汀钙三水合物的制备方法
|
|
MY180626A
(en)
|
2013-11-15 |
2020-12-03 |
Akebia Therapeutics Inc |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
|
|
CN104945300B
(zh)
*
|
2015-06-17 |
2017-05-10 |
北京嘉林药业股份有限公司 |
一种ⅰ型阿托伐他汀钙的纯化方法
|
|
CN105085362B
(zh)
*
|
2015-09-18 |
2018-01-05 |
浙江海森药业有限公司 |
高纯度结晶型阿托伐他汀钙的制备方法
|
|
WO2025147589A1
(en)
|
2024-01-05 |
2025-07-10 |
Osanni Bio, Inc. |
Implants, compositions, and methods for treating retinal diseases and disorders
|